To date, 15 LQTS-susceptibility genes have been discovered, with 75% of clinically robust LQTS attributed to mutations in 3 genes that encode for critical potassium (KCNQ1, 30%-35%, LQT1; KCNH2, 25%-30%, LQT2) or sodium (SCN5A, LQT3, ≈5%-10%) ion channel α-subunits largely responsible for the cardiac action potential. [12] [13] [14] The remaining LQTS-susceptibility genes (LQT4-15) encode for either cardiac channels, channel-interacting proteins, or structural membrane scaffolding proteins that modulate channel function and collectively contribute to <5% of LQTS. 15, 16 Consequently, 20% of patients with a clinically strong diagnosis of LQTS remain genetically elusive and are labeled as genotype-negative LQTS.
With exception of the 3 major LQTS genes originally discovered in the mid-1990s after multigenerational wholegenome familial linkage studies and positional cloning, the majority of the minor LQTS-susceptibility genes have been discovered using a biological plausible, candidate-gene approach. Major technological advances in DNA sequencing have emerged recently, allowing for rapid whole-genome or whole-exome interrogation of patient samples for the identification of novel pathogenic mutations. In fact, several recent reports have used whole-exome sequencing (WES) approaches targeting a trio of affected and unaffected members within a pedigree to discover novel genetic substrates for a variety of noncardiac, heritable diseases. [17] [18] [19] [20] In this study, we performed a WES trio analysis approach on a large multigenerational, genotype-negative LQTS pedigree to identify a novel cause for classical, nonsyndromic, autosomal dominant LQTS followed by mutational analysis of the newly discovered genetic substrate in a large cohort of unrelated patients with robust clinical evidence for LQTS but a heretofore negative genetic test (ie, genotype-negative/phenotype-positive LQTS).
Methods

Study Subjects
A 15-member (8 affected, 5 unaffected, 2 unknown) multigenerational family, presenting with autosomal dominant inherited LQTS without syndactyly, cognitive impairments, facial dysmorphisms, or any other noncardiac clinical characteristics suggestive of TS ( Figure 1A ; Table 1 ), which remained genotype-negative after commercially available LQTS genetic testing, was referred to the Mayo Clinic Windland Smith Rice Sudden Death Genomics Laboratory for further research-based genetic testing. After written consent for this Institutional Review Board-approved study, medical records, including 12-lead surface ECGs, and peripheral blood lymphocytes were obtained for 12 family members. Genomic DNA was obtained using the Puregene DNA Isolation Kit (Qiagen, Inc, Valencia, CA). The symptomatic index case (QTc=498 ms), unaffected father (QTc=383 ms), and affected maternal aunt (QTc=479 ms) were selected for WES.
In addition, 102 unrelated patients (71 females, 98% white, average age at diagnosis=23±16 years, and an average QTc of 516 ms±6.6 SEM) with robust clinical evidence for LQTS (QTc≥480 ms or a Schwartz-Moss 21 score ≥3.5) who were referred to our laboratory previously for genetic testing were included (see Table 2 for cohort demographics). All patients signed written consent for this Institutional Review Board-approved study. All 102 patients were mutation negative after LQTS mutational analysis (by denaturing high-performance liquid chromatography and DNA sequencing) of the 3 major LQTS genes: KCNQ1, KCNH2, and SCN5A and 8 minor LQTS genes: AKAP9, ANKB, CAV3, KCNE1, KCNE2, KCNJ2, SCN4B, and SNTA1. In addition, all patients were negative for large KCNQ1 and KCNH2 gene rearrangements (whole single or multiple exon deletions/duplications) after gene-specific copy number variation analysis using multiplex ligation-dependent probe amplification technique.
Whole-Exome Sequencing
WES and subsequent variant annotation was performed on genomic DNA derived from the symptomatic index case (III.2, Figure 1A ; Table 1 ; Figure IA in the online-only Data Supplement), unaffected father (II.1, Figure 1A ; Table 1 ; Figure IB in the online-only Data Supplement), and affected maternal aunt (II.5, Figure 1A ; Table 1 ; Figure IC in the online-only Data Supplement) by the Mayo Clinic Advanced Genomics Technology Center and Bioinformatics Core facilities. Paired-end indexed libraries were prepared using the manufacturer's protocol (Agilent, Santa Clara, CA). The whole-exome capture was carried out using SureSelect Human All Exon 50MB kit (Agilent; Santa Clara, CA The sequence data were processed for alignment, and variant calling and annotation was completed using Targeted REsequencing Annotation Tool. 22 The Targeted RE-sequencing Annotation Tool annotation included alignment to the human genome 37 (hg19) using Burrows-Wheeler Alignment (BWA), 23 duplicate read removal using PICARD (http://picard.sourceforge. net/), and Genome Analysis Toolkit (GATK) 24 for local insertion/deletion (INDEL) realignment and base quality score recalibration of aligned reads. Single-nucleotide variants (SNVs) and INDELs were then called using SNVMix 25 and GATK, 24 respectively. The SNVs and INDEL annotations provided by Targeted RE-sequencing Annotation Tool analysis were then filtered and summarized using custom Perl and shell scripts. The custom scripts intersected the SNVs of the 2 samples in the affected group (affected index case [III.2] and affected maternal aunt [II.5]) and intersected the SNVs of the sample in the unaffected case (unaffected father [II.1]). The SNVs in the unaffected group were then subtracted from the SNVs in the affected group to identify the novel SNVs shared by the symptomatic index case and affected maternal aunt. SNVs in the affected samples at sites with <5× coverage and variants present in either dbSNP, 26 
Systems Biology-Aided Exome Filtering
The LQTS interactome, 29 which features 1629 genes of the human genome that are considered to be the most likely genes that encode proteins that influence or regulate cardiac repolarization, thus representing possible candidate genes for LQTS, was used to determine which genes (harboring variants), shared between the index case and affected maternal aunt, could be potential LQTS candidates. Next, 3 systems biology-ranking algorithms, Endeavor 30 (http:// homes.esat.kuleuven.be/≈bioiuser/endeavour/tool/endeavourweb/ php), SUSPECTS 31 (http://www.genetics.med.ed.ac.uk.suspects/), and ToppGene 32 (http://toppgene.cchmc.org/prioritization.jsp), were used to rank the putative disease-causative genes and were accessed publicly through the internet. Default prioritization parameters were used for each algorithm. The 3 canonical LQTS disease-causing genes, KCNQ1, KCNH2, and SCN5A, were used as the 3 algorithms' training genes to rank identified mutationcarrying genes. Subsequently, the rare, shared variants that localized within the published LQTS interactome, CACNA1C, DMRTB1, DSCAML1, GLTSCR, SLC26A1, MAP1A, MARCKS, PPP1R12C, and SLC26A1 (listed alphabetically here), were prioritized in each of these algorithms. 
DNA Sanger Sequencing for Variant Confirmation and Cosegregation Analysis
Cell Culture and Transfection
HEK293 cells were transfected with plasmids encoding either wild type (WT)-or Pro857Arg-Ca v 1.2 with yellow fluorescent protein fused at the N-terminus (Antzelevitch et al 33 ) , β 2cN4 , and α 2 δ 1 in a 1:1:1 molar ration using Lipofectamine 2000 and cultured in DMEM+10% fetal bovine serum, 2 mmol/L L-glutamine, 100 U/mL penicillin, and 100 μg/mL streptomycin at 37°C+5% CO 2 as previously described (Best et al 34 ). HEK293 cell experiments were performed 40 to 48 hours after transfection.
Electrophysiology
Whole-cell ruptured patch clamp experiments were performed in HEK293 cells at 21°C to 24°C. The pipette solution consisted of (in On electric access, capacitive transients were obtained by applying a 5-mV hyperpolarizing pulse. Whole-cell Ca 2+ currents (I Ca,L ) were elicited at 10 mV increments from a holding potential of −80 mV and recorded using an Axopatch 200B amplifier (Molecular Devices, Sunnyvale, CA). Data were sampled at 25 kHz and filtered at 5 kHz, and leak and capacitive currents were subtracted using a P/4 protocol. Data are presented as current density by normalizing I Ca,L to cell capacitance. Data are plotted in Figure 2 as mean±SEM, and significance at each voltage (defined as P<0.05) was determined by Student t test using Origin 7.5 software (OriginLab, Northampton, MA).
Cell-Surface Biotinylation
HEK293 cells grown in 10 cm culture dishes were cooled to 4°C, washed 3× in ice-cold PBS, and biotinylated for 30 minutes with 0.5 to 1.0 mg/mL EZ Link Sulfo-NHS-LC-Biotin (Thermo Scientific Pierce Protein Research Products, Rockford, IL) at 4ºC. Cells were then washed twice in ice-cold Tris-buffered saline followed by an additional wash in PBS to remove biotinylation reagent. Cells were harvested directly by scraping and lysed in buffer containing 150 mmol/L NaCl, 20 mmol/L Tris-HCl (pH 7.4), 1% Triton X-100, 0.5 deoxycholic acid, and protease inhibitor cocktail containing 2 mmol/L phenylmethylsulfonyl fluoride, 50 µg/mL aprotinin, 50 µg/ mL benzamidin, 50 µg/mL leupeptin, and 5 µmol/L pepstatin A. For capture of cell-surface biotinylated proteins, 0.5 to 1.0 mg soluble protein lysate was incubated with 75 µL High Capacity NeutrAvidin agarose beads (Thermo Scientific Pierce Protein Research Products) for 1 to 2 hours at 4ºC. NeutrAvidin beads were washed 5×, and proteins were eluted by heating for 5 minutes at 95°C with SDS-PAGE sample buffer.
SDS-PAGE and Western Blotting
Protein samples were separated using SDS-PAGE and transferred to polyvinylidene difluoride membranes. Nonspecific binding sites were blocked using 5% (wt/vol) dried skim milk in Tris-buffered saline with 0.05% Tween-20. Membranes were probed with the following antibodies: rabbit anti-Ca v 1.2 (#AAC-003, Alomone Labs, Jerusalem, Israel), mouse antitransferrin receptor (clone H68.4, Invitrogen), and rabbit anti-GAPDH (#sc-25778, Santa Cruz Biotechnology, Santa Cruz, CA) overnight at room temperature. Membranes were washed subsequently 4× for 10 minutes before incubation in appropriate horseradish peroxidase-conjugated secondary antibody for 1 hour. After additional washes in Tris-buffered saline with 0.05% Tween-20, immunoreactivity was visualized using ECL Plus (GE Healthcare Life Sciences, Pittsburgh, PA). Membrane stripping was performed at 55ºC for 30 minutes in buffer containing 62.5 mmol/L Tris-HCl, pH 6.8, 2% SDS, 100 mmol/L β-mercaptoethanol, and 100 mmol/L DTT. Densitometric analysis was achieved using ImageJ (National Institutes of Health, Bethesda, MD).
CACNA1C Mutational Analysis
Comprehensive open reading frame and splice junction mutational analysis of the entire coding region (57 amplicons that encode 2139 amino acids) of CACNA1C (GenBank accession number NM_000719) was performed on genomic DNA derived from 102 unrelated LQTS diagnosed patients (described above) using polymerase chain reaction, denaturing high-performance liquid chromatography 
Results
Genotype-negative/Phenotype-positive Autosomal Dominant LQTS Pedigree
The index case is a 33-year-old white woman (III. Table 1 ) who presented at 27 years of age with a postpartum agonal breathing event. Subsequent medical history revealed multiple startle-triggered and exercise-induced syncopal events starting at the age of 13 years. Her ECG revealed a prolonged QTc of 498 ms ( Figure 1B ; Figure IA in the online-only Data Supplement). Her medical therapy included implantable cardioverter-defibrillator placement and a left cardiac sympathetic denervation. Because of complications, she had a brief period in which her implantable cardioverter-defibrillator was removed. Subsequent to implantable cardioverter-defibrillator removal, she had 1 more event while sleeping, which included shaking and agonal breathing, from which she spontaneously recovered. After this event, an implantable cardioverter-defibrillator was reimplanted. Her family history is positive for LQTS and a sudden unexplained infant death.
Screening ECGs were performed on 11 of the 12 available family members, and genomic samples were gathered from 12 family members. On the basis of ECG findings, 7 family members have borderline/prolonged QTc or a significant history of cardiac events. The 5 family members with normal ECGs were asymptomatic ( Figure 1A ; Table 1 ).
Overall, the family history and inheritance pattern indicated autosomal dominant LQTS. One of the index case's maternal aunts, II.3, suffered from hospital cardiac arrest at 44 years of age, which resulted in significant neurological damage. A second maternal aunt, II.4, died during infancy of unknown cause. A third maternal aunt, II.5, suffered 1 syncopal event during pregnancy (QTc=479 ms, ECG available in Figure IC in the online-only Data Supplement). The index case's daughter, IV.1, has been treated with prophylactic β-block therapy since 8 years of age (QTc=450 ms). The index case's asymptomatic mother, II.2, has a prolonged QTc of 486 ms. The ECG of the index case's asymptomatic maternal uncle, II.6, shows sinus bradycardia, early repolarization, and a QTc of 454 ms (Table 1) .
WES for Novel Pathogenic Substrate Identification in a Large Multigenerational LQTS Pedigree
Genomic DNA samples of the trio of participants in the pedigree, index case (III.2), her affected maternal aunt (II.5), and unaffected father (II.1), were analyzed by WES. Among the 3 samples, ≈98% of the reads were mapped, and ≈44% of the reads were within the target region ( Table I in The detected single-nucleotide variations and INDELs were configured in a spreadsheet so subsequent filtering strategies could be used to identify potential pathogenic variants. After alignment and SNV calling, 46 307 genetic variants were present in the exome of the index case ( Figure 1C ; Table I in the online-only Data Supplement). After exclusion of common variants present in 1000 Genomes Project, 27 dbSNP, 26 and 200 Beijing Genomics Institute exomes 28 as well as all synonymous SNVs, 263 variants remained ( Figure 1C ; Table I in the online-only Data Supplement). Variants shared between the index case (III.2) and the unaffected father (II.1) and unshared variants between the index case (III.2) and the affected maternal aunt (II.5) were subtracted, leaving 110 rare variants present in both the index case and the maternal aunt (data not shown).
Of these 110 remaining variants, only 8 variants, 6 SNVs and 2 InDels (CACNA1C c.2570C>G, p.Pro857Arg; DMRTB1 c.248_252dupCCGCCC, p.Ala83_Ala84dup; DSCAML1 c.6307G>A, p.Ala2103Thr; GLTSCR1 c.91A>G, p.Ser31Gly MAP1A c.2842G>A, p.Val948Ile; MARCKS c.552_557dupTGAGGC, p.Glu185_Ala186dup; PPP1R12C c.188A>G, p.Asp83Gly; and SLC26A1 c.2007C>G, p.Asp669Glu), resided in genes that were present in the previously published 1629 node LQTS interactome, 29 suggesting these 8 variants as the best candidates for pathogenicity in this multigenerational LQTS pedigree.
Candidate-gene priority ranking using 3 in silico bioinformatic/systems biology algorithms (ToppGene, 32 Endeavour, 30 and Suspects 31 ) with KCNQ1, KCNH2, and SCN5A serving as the network training genes, unanimously ranked the L-type calcium channel (LTCC) encoded by CACNA1C as the number 1 LQTS-causing candidate gene, followed by SLC26A1, MAP1A, DMRTB1, DSCAML1, GLTSCR1, PPP1R12C, and then MARCKS (Table 3 ). In addition, none of the 102 shared variants that resided outside the LQTS interactome scored higher than CACNA1C with any of the in silico tools (data not shown).
In addition to the in silico analysis, which ranked CACNA1C unanimously as the most likely LQTS-associated candidate gene within the exomes of these patients, we analyzed the genomic DNA from all 12 family members (7 affected and 5 unaffected) for the presence/absence of all 8 variants. Consistent with the in silico prediction, Pro857Arg-CACNA1C was the only variant with complete cosegregation with the LQTS phenotype (ie, present in all affected and absent in all unaffected family members) in this multigenerational pedigree ( Figure 1A ; Table 1 ).
The Pro857Arg-CACNA1C missense mutation is a single-nucleotide genetic variant (c. 2570 C>G) resulting in the substitution of a neutral, nonpolar amino acid (proline, pro) for a positively charged amino acid (arginine, arg) at position 857 of the LTCC (also annotated as Ca v 1.2). This putative pathogenic mutation was absent among 1094 (1000 Genomes Project), 27 5379 (National Heart, Lung, and Blood Institute GO Exome Sequencing Project), 35 12 000 (12000 exome chip), 36 
In Vitro Functional Analysis of the Pro857Arg-CACNA1C
To further understand the effect that Pro857Arg has on the CACNA1C channel, we used the ruptured whole-cell patch clamp technique to determine whether there were electrophysiological differences between Pro857Arg-and WT-CAC-NA1C currents. Functional characterization of the mutation using whole-cell patch clamp technique in a heterologous HEK293 expression system revealed a gain-of-function phenotype with a 113% increase in peak I Ca,L at +10 mV compared with WT ( Figure 2) , which may lengthen the cardiac action potential and prolong the QT interval. Because the Pro857Arg-CACNA1C mutation lies in a PEST domain, we hypothesized that the Pro857Arg mutation may impair the normal degradation of Ca v 1.2, thus leading to an increase in surface membrane channels and functional I Ca,L . To test this, we performed cell-surface biotinylation experiments using HEK293 cells transiently expressing WT-CACNA1C or Pro857Arg-CACNA1C along with auxiliary β 2cN4 and α 2 δ 1 subunits. Figure 3 shows a representative Western blot demonstrating that the Pro857Arg mutation leads to an increase in NeutrAvidin-isolated (and thus plasma membrane localized) Ca v 1.2 signal compared with WT ( Figure 3A , top left panel). Detection of endogenous transferrin receptor was included to show that expressing the Pro857Arg-CACNA1C mutant did not lead to a nonspecific increase in surface membrane proteins ( Figure 3A, middle left panel) . Densitometric analysis of 9 independent experiments showed a mean 64% increase in surface membrane expression of Pro857Arg-CACNA1C relative to WT-CACNA1C ( Figure 3B; P=0.05) . No significant difference was detected in the total cellular Ca v 1.2 signal between Pro857Arg and WT ( Figure 3A , top right panel; Figure 3C ). Probing for the cytosolic protein GAPDH ensured that the biotinylation reagent did not significantly cross the cell membrane ( Figure 3A , bottom panels). Figure 1 and Table 1 . 
Spectrum and Prevalence of CACNA1C Variants in a Large Cohort of Unrelated Patients With Genotype-negative/Phenotype-positive LQTS
After comprehensive mutational analysis of CACNA1C, we identified 3 novel, putative pathogenic missense variants in 3/102 (2.9%) unrelated genotype-negative/phenotypepositive LQTS patients (Table 4 ; Figure 4 ). Two of these 3 CACNA1C variant-positive patients were women. All 3 missense variants (c.2500A>G, p.Lys834Glu; c.2570C>T, p.Pro857Leu; and c.5717G>A, p.Arg1906Gln) were absent in 680 ethnically matched (white) controls, 1094 subjects from the 1000 Genomes Project, 27 5379 subjects from the NHLBI GO Exome Sequencing Project, 35 and the 12000 Exome Chip. 36 Interestingly, 2 of the missense variants (Lys834Glu and Pro857Leu) localize to the same critical PEST domain where the original mutation (Pro857Arg) discovered in the multigenerational LQTS pedigree resides (Figure 4 ). In fact, 1 of the variants (Pro857Leu) affects the same amino acid residue (Proline 857) as the LQTS-causing mutation identified in the pedigree. A third variant (Arg1906Gln) localizes closely to the recently described stromal interaction molecule 1 (STIM1) binding domain (amino acid residues 1806-1905) in Ca v 1.2's C-terminus, where STIM1 is a Ca 2+ sensor of the endoplasmic reticulum and interacts with the CACNA1C, resulting in a decrease of LTCC-mediated current, as well as chronically triggers LTCC internalization, suppressing channel function. [39] [40] [41] Importantly, like the affected subjects within the multigenerational pedigree, none of these 3 CACNA1C variant-positive subjects exhibits any clinical characteristics suggestive of TS. Instead, the Lys834Glu variant was identified in a 15-yearold white girl with a personal history of syncope, QTc of 475 ms, and a negative family history. The Arg1906Gln variant was identified in a 39-year-old white woman who presented with palpitations, syncope, a QTc of 513 ms, and negative family history.
Similar to the multigenerational pedigree that yielded our CACNA1C discovery with its Pro857Arg mutation, the Pro857Leu missense variant was identified in an asymptomatic 15-year-old white boy who was diagnosed with LQTS (QTc of 514 ms) after the sudden unexplained death of his 12-year-old sister during sleep. His mother, maternal grandmother, maternal great uncle, and maternal great aunt all have a previous history of syncopal events during childhood. Genomic DNA was available for the 12-year-old sister's unaffected father, affected mother, and affected maternal grandmother. Both the affected mother and affected maternal grandmother were positive for Pro857Leu whereas the unaffected father was negative (data not shown). DNA was not available for either the affected maternal great uncle or affected maternal great aunt.
Discussion
WES is a highly efficient means of interrogating the DNA sequence of the entire protein-encoding region of virtually every gene in the human genome for a given patient sample to potentially elucidate the underlying genetic mechanism of disease. However, in doing so, an investigator is often faced with tens of thousands of genetic variants, per patient DNA sample, that must be sifted through to identify the possible diseasecausative variant. To identify potential candidate genes, we used publicly available internet-based gene-prioritization tools like ToppGene, 32 Endeavour, 30 and SUSPECTS 31 to bioinformatically rank candidate genes 20 by training network algorithms to search a user-defined gene list and prioritize genes for disease candidacy based on similarities to a set of user-defined training genes (ie, known disease-causing genes such as KCNQ1, KCNH2, or SCN5A for LQTS). Specifically for LQTS analysis, the previously published 1629 LQTS interactome 29 (encompassing a set of genes with the greatest potential to regulate cardiac repolarization) proved to be a useful tool in further filtering variants down to a manageable number of <10 candidates.
Here, our study is the first to use a next-generation WES trio approach 17 followed by LQTS interactome 29 variant filtration and disease-network analysis-based gene-ranking prioritization to discover a novel putative LQTS disease-causative missense mutation, Pro857Arg-CACNA1C, that properly cosegregated with the LQTS phenotype in a large, multigenerational pedigree with autosomal dominant genotype-negative/ phenotype-positive LQTS. In addition to cosegregation, this mutation produced a gain-of-function effect on heterologously expressed Pro857Arg Ca v 1.2 channels with a uniform increase in I Ca,L density. The electrophysiological findings are consistent with the increase in surface membrane channels identified by biotinylation experiments. Because I Ca,L contributes to phases 2 and 3 of the action potential, a scaled increase in this depolarizing current might increase action potential duration and the associated QT interval. Transgenic overexpression of Ca v 1.2 channels in the mouse heart has demonstrated an increase in action potential duration, but this is accompanied by complex electric remodeling of multiple ionic currents as well as hypertrophy. 42 Thus, the extensive feedback regulation of Ca v 1.2 channels and possible electric remodeling of multiple currents in the heart limit the ability to precisely extrapolate the increase in I Ca,L observed in the heterologous expression studies to native human heart.
CACNA1C encodes for the α-subunit of the LTCC (Ca v 1.2), which is critical for cellular excitability and the cardiac action potential, excitation-contraction coupling, and regulation of gene expression. 43, 44 Interestingly, 3 (Lys834Glu, Pro857Leu, and Pro587Arg) of the 4 variants discovered in our study localize to a key PEST domain of the II-III linker of the LTCC α-subunit. PEST sequences, rich in proline (P), glutamic acid (E), serine (S), and threonine (T), act to signal rapid protein degradation through the cell's quality control system. 37, 38 A recent study has demonstrated that Akt (also known as protein kinase B) regulates LTCC channel protein stability by preventing Ca v 1.2 PEST sequence recognition and hence promoting stability of the channel complex, resulting in increased macroscopic currents. 45 However, mechanisms regulating the membrane stability of the LTCC are understood poorly, and how the unmasked PEST sequence leads to channel proteolysis is unknown. Our functional studies revealed that the mutation Pro857Arg-CACNA1C precipitates a 113% increase in peak I Ca,L at +10 mV compared with WT. We have also shown that Pro857Arg leads to a 64% increase of surface membrane expression compared with WT. The combination of these findings leads to our hypothesis that Lys834Glu-, Pro857Leu-, and Pro857Arg-Ca v 1.2 may disrupt the functional PEST sequence and lead to increased channel protein stability, increased number of surface membrane LTCCs as seen through biotinylation experiments, and increased I Ca,L, as seen through our electrophysiological studies of Pro857Arg-CACNA1C. The increase in I Ca,L might increase the action potential duration and contribute to the genesis of early after depolarizations and potentially Ca 2+ overload-related delayed after depolarizations, resulting in an LQTS phenotype with the propensity for potentially lethal arrhythmias.
The Arg1906Gln variant resides one amino acid away from the Ca v 1.2 C-terminus STIM1-binding domain. STIM1, the main activator of store-operated Ca 2+ channels, directly suppresses depolarization-induced opening of the voltage-gated Ca 2+ channel Ca v 1.2. STIM1 binds to the C-terminus of Ca v 1.2 through its Ca 2+ release-activated Ca 2+ activation domain, acutely inhibits gating, and causes longterm internalization of the channel from the membrane. [39] [40] [41] Because of its proximity, Arg1906Gln could alter STIM1 binding to CACNA1C, preventing the internalization of the channel, leading to an increased number of channels on the membrane and a gain-of-function in Ca v 1.2 currents. All the identified variants (Pro857Arg, Pro857Leu, Lys834Glu, and Arg1906Gln) seem to potentially involve channel internalization and protein degradation pathways. Further characterization of these variants may give a deeper understanding of CACNA1C protein regulation.
Interestingly, 3 unique CACNA1C gain-of-function missense mutations (Gly406Arg in CACNA1C's alternative exon 8a, Gly406Arg in exon 8, and Gly402Ser in exon 8) have been described in TS, an extremely rare (fewer than 20 people worldwide have been reported), multisystem disorder associated with extreme QT prolongation, syndactyly, autism spectrum disorder, and a myriad of other organ system abnormalities that often lead to early childhood death. [8] [9] [10] [11] Importantly, none of the CACNA1C variant-positive individuals in the pedigree or the cohort study exhibits syndactyly, cognitive impairments, facial dysmorphisms, autism spectrum disorders, or any other noncardiac clinical characteristics suggestive of TS. Additionally a majority of the members within the pedigree harboring the Pro857Arg-CACNA1C mutation have survived into adulthood, which is extremely unlikely in patients with TS.
Although previously described in TS, no CACNA1C mutations have been reported for nonsyndromic LQTS. With our functional studies confirming Ca v 1.2 gain of function as the cellular basis for the CACNA1C mutation-positive patient's LQTS phenotype, a paradox has emerged. Namely, how can some gain-of-function mutations, like Gly406Arg in the alternatively spliced exon 8A, result in the multiorgan system phenotype of TS whereas other missense mutations, like Pro857Arg, yield a cardiac-only phenotype of autosomal dominant LQTS? Because this is a new discovery, it is not surprising that the answer is elusive.
Several potential mechanisms have been proposed, but the most likely explanation is that CACNA1C is expressed as many different isoforms throughout the body. Therefore, variable splice isoforms and differences in the corresponding accessory subunits (such as the β-subunit) vary among skeletal, cardiac, and neuronal tissues. In fact, a single nonsynonymous CACNA1C variant (Ala39Val), identified in patients with Brugada syndrome, results in a trafficking defect of the channel, which is apparent only in cells expressing the cardiac isoforms of CACAN1C while being normal in the context of the neuronal rat isoform. 46 Therefore, it is possible that the variants identified here will perturb only the cardiac isoforms of the channel or auxiliary subunits and will have minimal or no effect on CACNA1C expressed in other tissues, thereby leading exclusively to cardiac disease.
Given that all unrelated TS patients described to date have either the same exact sporadic de novo Gly406Arg (16 cases) mutation in exon 8a, Gly406Arg in exon 8 (1 case), or a mutation residing only 4 amino acids away (Gly402Ser, 1 case) suggests that this specific amino acid residue or region of CACNA1C may have a unique functional effect on the LTCC in multiple-organ systems whereas mutations in other regions of CACNA1C may produce a cardiac-only phenotype. All 3 TS mutations lead to an impaired open-state voltage-dependent inactivation of the LTCC whereas Pro857Arg leads to an increase in peak I Ca,L current presumably through an increase in cell-surface membrane expression of LTCCs without perturbing either channel kinetics or gating properties.
Limitations
To date, only 1 of the 4 identified CACNA1C variants have been characterized functionally. Further functional studies will be necessary to definitively understand the pathogenic mechanisms underlying these CACNA1C variants and their implications in LQTS. HEK293 cells have specific current/ kinetic properties and trafficking properties that may not be reflective of the properties of cardiomyoctes. Alternative approaches such as adenoviral transduction of primary cardiac myocytes or patient-specific induced pluripotent stem cell-derived cardiomyocytes may overcome some of the limitations of the heterologous expression system, but these approaches are beyond the scope of this study.
Conclusions
The combination of the 4 identified variants (absent in nearly 15 000 non-LQTS individuals) as well as familial cosegregation with disease for 2 variants (Pro857Arg and Pro857Leu) suggests that perturbations in the CACNA1C-encoded LTCC are bona fide pathogenic substrates for classical, nonsyndromic, autosomal dominant LQTS with implications for LQTS genetic testing. If this frequency is validated in subsequent studies, CACNA1C may fall after KCNQ1, KCNH2, SCN5A, and KCNE1 and account for ≈1% of LQTS.
